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Dear Editor,
In their publication in Pharmacoeconomics Open,
Akpinar et al. [1] reported the results of their review of
methods for forecasting drug prices for economic eval-
uations. This was an interesting article, and I agreed
with most of the conclusions. However, I disagree that
prices forecast using the price of a close substitute on
the same market may be more reliable. This conclusion
may be biased because of market-specific aspects that
were not incorporated in the study.
Akpinar et al. [1] obtained the actual (post-launch)
prices from official sources in the USA or Canada.
However, some of the economic analyses were con-
ducted for different markets. The mechanisms for con-
trolling prices differ between markets, and neglecting to
account for these differences may introduce bias. Hence,
the forecasting efficiency ([A - E]/E index proposed by
Akpinar et al. [1], where A is the actual and E is the
expected or forecast price of a drug) should be calcu-
lated using current prices in the same market for eco-
nomic evaluation. The updated information for economic
evaluations conducted outside of the USA and Canada
[2, 3] are presented in Table 1. Although the general
conclusions did not change (there is still no trend), the
forecasting efficiency did change drastically when mar-
ket-related aspects were incorporated. Additionally, there
is no advantage to the forecasting method that utilizes
the price of a close substitute, i.e. the average absolute
value of the (A - E)/E index for a method based on a
close substitute and others equalled—after correction—
84 and 45%, respectively. Those values in the study of
Akpinar et al. [1] were 68 and 80%, respectively, indi-
cating slightly better performance of the method using
the price of a close substitute. That conclusion no longer
holds true after the adjustment.
Additionally, the study touched on the conclusion that
the generalizability of economic evaluations may be lim-
ited, i.e. the cost effectiveness of a drug in a specific market
may not translate well to other markets, especially when
the economic evaluation is based on forecast prices. Cau-
tion is always recommended when accepting a cost-effec-
tiveness ratio based on forecast prices. Perhaps the best
way to minimize the risk of misinterpreting the results of
an economic evaluation and to limit the forecast price
impact is to show a ‘threshold price’ as an endpoint (in
base-case and all scenarios of sensitivity analyses). The
‘threshold price’ informs decision makers about the max-
imal price of a drug at which using it is still cost effective
(e.g. associated with a cost-effectiveness ratio below the
threshold [4] or less costly, depending on the type of
economic evaluation). Additionally, the ‘threshold price’
can be presented as a function of the threshold (Fig. 1),
price of a well-known drug used in the same indication
across markets as a reference, or both (Fig. 2). For exam-
ple, a new biological agent for the treatment of inflam-
matory bowel diseases (e.g. vedolizumab, ustekinumab)
can use infliximab as a reference in threshold pricing pre-
sentations. Such results can be used to obtain a ‘threshold
price’ for another market, although it is still not adjusted
for all differences (e.g. medical services valuation,




1 Pharmacoeconomic Research Center, Krako´w, Poland
PharmacoEconomics Open (2017) 1:69–70
DOI 10.1007/s41669-016-0008-x
treatment patterns). The approach can reduce the risk of
misinterpretation and solve major problems in the fore-
casting of pharmaceutical prices for economic evaluations.
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Table 1 The forecasting efficiency of pharmaceutical prices for the markets outside of the USA and Canada
Ruconest (conestat alfa) Prolia (denosumab)
Study Kawalec et al. (2013) [2] Hiligsmann et al. (2010) [3]
Country (year of price forecasting) Poland (2012) Belgium (2009)
Forecast price PLN4816.52 EUR95.48
Forecast price inflated to 2016 PLN4825.89 EUR106.40
Actual price (source) PLN3702.66 (http://www.mz.gov.pl) EUR180.21 (http://www.cbip.be)
[A - E]/E index (origin market) (%) -23.3 69.4
[A - E]/E index (US/Canada market) [1] (%) 127.5 5.1
A actual price, E expected (forecast) price
Fig. 1 Example of association between the ‘threshold price’ and
willingness to pay for additional health effect (the threshold)
Fig. 2 Example of association between the ‘threshold price’, the
threshold, and price of a reference drug
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